比卡鲁胺所致PSMA PET阳性男性乳腺发育在雄激素剥夺治疗后的可逆性
一名78岁接受比卡鲁胺治疗前列腺癌的男性因PSA逐渐升高行PSMA PET/CT,显示双侧乳腺实质放射性摄取,为比卡鲁胺单药治疗已知但罕有报道的效应。扫描同时显示骨和淋巴结转移,患者开始亮丙瑞林注射;睾酮水平下降三个月后乳腺组织放射性摄取消退,表明PSMA高摄取的比卡鲁胺所致男性乳腺发育是可逆的。
要点
- 比卡鲁胺单药治疗可致PSMA PET/CT双侧乳腺实质高摄取,属已知但罕有报道的效应。
- 该患者PSMA PET/CT同时显示骨和淋巴结转移进展。
- 睾酮水平下降三个月后乳腺放射性摄取消退,提示该效应可逆。
核心结论
- PSMA高摄取的比卡鲁胺所致男性乳腺发育在睾酮水平下降后是可逆的。
研究设计与样本
- 病例报告:一名78岁因前列腺癌接受比卡鲁胺治疗的男性,因PSA逐渐升高行PSMA PET/CT评估。
主要发现
- PSMA PET/CT显示双侧乳腺实质放射性摄取,为比卡鲁胺单药治疗已知但罕有报道的效应。
- 同次扫描显示骨和淋巴结转移进展,患者开始亮丙瑞林注射。
- 睾酮水平下降三个月后,乳腺组织放射性摄取消退。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
A 78-year-old man receiving bicalutamide for prostate cancer was referred for a PSMA PET/CT scan to evaluate his gradually rising prostate-specific antigen level. The PSMA PET/CT revealed gynecomastia with radiotracer uptake in bilateral breast parenchyma, a known but rarely reported effect of bicalutamide monotherapy. This scan also demonstrated metastatic progression of his disease in bone and lymph nodes, and he was started on leuprolide injections. Three months after a decrease in his testosterone level, the radiotracer uptake in his breast tissue had resolved, demonstrating that PSMA-avid bicalutamide-induced gynecomastia is reversible.
引用
- Muniz M, Childs DS, Orme JJ, et al. Reversibility of Bicalutamide PSMA PET-Positive Gynecomastia With Androgen Deprivation Therapy. Clin Nucl Med. 2024. PMID: 38377363. doi:10.1097/RLU.0000000000005084
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。